STOCKHOLM, May 23, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALTX) (STOCKHOLM: CALTX):
Target market expansion following full approval in the US
JANUARY - MARCH 2024 (COMPARED TO JANUARY - MARCH 2023)
"In Q1 we generated another record quarter in terms of demand with 705 enrollments and 354 new prescribers. We are very excited over this positive trend, and we continue to see strong demand in Q2." - CEO Renée Aguiar-Lucander.
KEY TAKEAWAYS FROM Q1, 2024
KEY EVENTS AFTER THE REPORTING PERIOD
KEY EVENTS UPCOMING 6 MONTHS
Outlook for 2024: Unchanged
Calliditas expects continued revenue growth:
Total net sales from the Nefecon franchise, including milestones, are estimated to be USD 150-180 million for the year ending December 31, 2024.
Investor Presentation:
May 23, 2024 14:30 CET
Link to webcast: Calliditas Therapeutics Q1 Report 2024 (financialhearings.com)
To participate via conference call register via this link: Call Access (financialhearings.com)
For further information, please contact:
Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel.: +46 76 403 35 43, Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
The information in the report is information that Calliditas is obliged to make public pursuant to the EU Market Abuse Regulation. The information was sent for publication, through the agency of the contact person set out above, on May 23, 2024, at 7:00 a.m. CET.
The following files are available for download:
Q1 2024 Calliditas ENG |
Last Trade: | US$40.00 |
Daily Volume: | 0 |
Market Cap: | US$1.080B |
August 13, 2024 July 26, 2024 June 18, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB